NCT02407509: Phase I Trial of RO5126766 Alone and in Combination With Everolimus

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS, BRAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only patients with mutation in the RAS-RAF-MEK pathway (including BRAF, KRAS & NRAS) will be eligible for Part 2 of the study
Exclusions: Patients with brain metastases

Comments are closed.

Up ↑